#United States #Foster City, California #Single Cell #1Cell.Ai #BioSkryb

Strategic Partnership Between 1Cell.Ai and BioSkryb

In an exciting development for the field of genomic research, 1Cell.Ai, recognized globally for its advancements in single cell precision diagnostics, has entered a strategic alliance with BioSkryb Genomics, a leader in the single cell multi-omics domain. This partnership is poised to redefine the methodologies of single cell analysis and provide significant breakthroughs in cancer detection and treatment.

The Purpose and Benefits of the Partnership

The crux of this collaboration lies in the merging of 1Cell.Ai's innovative OncoIncytes platform with BioSkryb's proprietary single cell amplification and multi-omic technologies. The goal is to develop advanced solutions that allow researchers and healthcare professionals to detect and analyze rare genetic mutations within single cells with an accuracy previously deemed unattainable. This capability is particularly vital for cancer research, facilitating early diagnosis and the development of more targeted therapies.

By integrating their technologies, the pairing aims to empower researchers with the tools necessary for isolating circulating tumor cells (CTCs) down to one cell in a billion—a breakthrough that could accelerate research timelines and enhance the precision of therapeutic approaches, especially for antibody-drug conjugates (ADCs).

Insights from Leadership

Nobel Laureate Dr. James Rothman, who serves on the board of 1Cell.Ai, expressed enthusiasm about the venture, highlighting that the combination of BioSkryb's cutting-edge multi-omics chemistry with 1Cell.Ai's expertise in single cell isolation will illuminate new pathways for understanding cellular behavior and the underlying mechanisms of diseases that challenge modern medicine.

1Cell.Ai's CEO, Mohan Uttarwar, echoed this sentiment by stating their excitement in collaborating with BioSkryb to push the boundaries of what is achievable in single cell analysis. He emphasized that together, they aim to provide groundbreaking solutions crucial for addressing pressing challenges faced in biology and drug discovery.

Comprehensive Analysis Capabilities

With this integrated platform, researchers will now be able to conduct detailed analyses on critical cellular components. Single cells will be subjected to thorough characterization of their DNA, RNA, and protein content, thus facilitating insights into disease progression and treatment efficacy. The advancements in technology will not only enhance the scope of research available but will also contribute substantially to advancing clinical diagnostics.

Background on 1Cell.Ai

1Cell.Ai is dedicated to elevating the precision of oncology diagnostics. Their OncoIncytes platform enables researchers to examine single cells by integrating multi-omic profiles—optimizing the chance for discovering new biomarkers essential for targeted therapies like ADCs. The platform is notable for its ability to isolate live single cells from blood samples, which is critical for identifying therapeutic targets.

Insight from BioSkryb Genomics

BioSkryb Genomics, utilizing its proprietary Primary Template Amplification (PTA) technology, allows for characterization of whole genomes and transcriptomes at the single-cell level. Their flagship products, including ResolveDNA and ResolveOME, provide unparalleled insights into the molecular underpinnings of diseases and are instrumental in driving forward the capabilities of genetic research.

Suresh Pisharody, CEO of BioSkryb, stated that this collaboration heralds a significant advancement in the domain of single cell research and enables an understanding of diseases at a molecular level, thereby paving the way for significant medical discoveries.

Moving Forward

The combined efforts of 1Cell.Ai and BioSkryb signify a monumental shift in how single cell technologies are applied in both research and clinical settings. As healthcare continues to advance, partnerships like this one are crucial for unlocking future discoveries that will undoubtedly improve patient outcomes and lead to the development of next-gen therapies.

Media inquiries can be directed to [email protected]